Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Terrell On ‘Relentless’ Digital Consumption Across the Spectrum

Executive Summary

GSK’s first chief digital and technology officer shares with Scrip her views on things digital that could potentially transform the pharmaceutical business, the ex-Walmart executive noting how digital touch points with physicians are improving “in every single geography and every single product.”

You may also be interested in...



2021 Saw India Enable Accelerated Regulatory Pathways – Can It Become The Norm?

India saw a raft of vaccine and drug approvals in 2021, backed by pandemic-related accelerated regulatory processes, and outlined its intent to step up biopharma innovation in the country.  Pharma wants some of the regulatory flexibility to stay, though experts are seeking increased transparency in the overall approach.

More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?

The vaccines segment continues to draw the interest of participants beyond those firms with a traditional core presence, with new players largely building partnered capabilities around COVID-19 inoculations. Are these merely opportunistic forays or will the competitive landscape for vaccines stand altered more widely?

Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments

Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel